In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer,
incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of …

Ovarian cancer is the second most common cause of gynecologic cancer death in women
around the world. The outcomes are complicated, because the disease is often diagnosed …

Background Ovarian cancer continues to have a poor prognosis with the majority of women
diagnosed with advanced disease. Therefore, we undertook the UK Collaborative Trial of …

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and
Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants …

Epithelial ovarian cancer generally presents at an advanced stage and is the most common
cause of gynaecological cancer death. Treatment requires expert multidisciplinary care …

In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and
14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society …

Hereditary breast and ovarian cancer syndrome (HBOC) is clinically defined by family
history criteria, and molecularly defined by identification of germline pathogenic variants …

Ovarian cancer (OC) is a heterogeneous disease with the highest mortality rate and the
poorest prognosis among gynecological malignancies. Because of the absence of specific …

Financial Disclosure Prof. Menon has stock ownership and has received research funding
from Abcodia Ltd, a UCL spinout company with an interest in biomarkers and commercial …

Purpose There are no internationally agreed upon clinical guidelines as to which women
with gynecological cancer would benefit from Lynch syndrome screening or how best to …